



Direction de la recherche  
et du développement

07<sup>th</sup> September 2022

EudraCT : 2019-004899-19

**ADJUVANT PALBOCICLIB + LETROZOLE COMBINATION FOR HORMONE  
RECEPTOR-POSITIVE / HER2-NEGATIVE INTERMEDIATE RISK BREAST CANCER**

**APOLON study**

This study was submitted to authorities and approved, however the study was stopped without any patients being recruited, therefore no report was created.

A handwritten signature in blue ink, appearing to read "N. AIT RAHMOUNE", is written over a horizontal line.

**N. AIT RAHMOUNE**

Director of Regulatory Affairs and Pharmacovigilance  
Unicancer

Okabè  
67, avenue de Fontainebleau  
94270 Le Kremlin-Bicêtre

Adresse postale :  
101, rue de Tolbiac  
75654 Paris cedex 13  
France  
T. + 33 (0)1 44 23 04 04

Siret FNCLCC : 314 559 139 000 14  
Code APE FNCLCC : 9499Z

[www.unicancer.fr](http://www.unicancer.fr)